The results showed that PD-1/PD-L1 inhibitor combined with chemotherapy can reduce the risk of tumor progression (HR=0.60, 95% CI: 0.55-0.65) and the risk of death (HR=0.71, 95% CI: 0.58-0.90) (50). The gene discussed is CD274; the disease is neoplasm.